Skip to main content
Equibles
ISCO logo

ISCO · International Stem Cell CORP · Metrics

Track ISCO — free

Use ISCO with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ISCO.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.18 -0.08 (-31.31%) At close · Oct 21
Rebalance outlook locked
Going-concern doubt — flagged Aug 13, 2026

Substantial doubt about the company's ability to continue as a going concern.

“These circumstances raise substantial doubt about the Company's ability to continue as a going concern.”
View the 10-Q filed Aug 13, 2026
Market Cap
$1.44M
Shares
8.00M
Volume · Oct 21 242.16K Avg daily vol (3M) 35.55K

ISCO metrics

77 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.18
Market cap
$1.44M

Price action

20 metrics
Price change (1W)
-32.2%
Price change (30D)
-45.9%
Price change (3M)
+5.1%
Price change (6M)
+27.6%
Price change (YTD)
+27.6%
Price change (1Y)
+19.1%
Trailing year
Price change (5Y)
-64.3%
52-week high
$0.51
52-week low
$0.12
Change from 52-week high
-65.0%
Change from 52-week low
+48.8%
Annualized volatility
191.2%
Annualized volatility (3M)
—
Beta
-0.9
RSI (14D)
30.2
Price vs SMA 50
-48.3%
Price vs SMA 200
-14.2%
Avg volume (3M)
35,551
Relative volume
6.8
Average dollar volume
$11,867

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
8.00M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
0.2×
reciprocal yield 660.3%
P / book
—
FCF yield
23.1%
TTM · current market cap
Buyback yield
—
P / FCF
4.3
reciprocal yield 23.1%
P / operating cash flow
3.9
reciprocal yield 25.6%
Earnings yield
-40.4%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
55.0%
Operating margin
-4.7%
Trailing 12 months
Net margin
-6.1%
Gross profit (TTM)
$5.23M
Operating profit (TTM)
−$444,000
Net income (TTM)
−$582,000
Trailing 12 months
Diluted EPS (TTM)
$-0.07
FCF margin
3.5%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$1.19
Gross profit per diluted share (TTM)
$0.65
Operating profit per diluted share (TTM)
$-0.06
EBITDA per diluted share (TTM)
$-0.04
Net income per diluted share (TTM)
$-0.07
Operating cash flow per diluted share (TTM)
$0.05
Free cash flow per diluted share (TTM)
$0.04
Capital expenditures per diluted share (TTM)
$0.00
R&D per diluted share (TTM)
$0.08
Stock compensation per diluted share (TTM)
$0.03
Book value per share
$-0.51

Growth

11 metrics
Revenue growth YoY
+9.3%
Year over year
Net income growth YoY
-155.0%
Revenue (TTM)
$9.51M
Trailing 12 months
EPS growth YoY
-200.0%
Shares change YoY
+0.0%
Year over year
Revenue CAGR (3Y)
+3.6%
Revenue CAGR (5Y)
+5.0%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-11.5%
Debt / equity
—
Current ratio
0.8
EBITDA (TTM)
−$272,000
Free cash flow (TTM)
$333,000
Quick ratio
0.4
Interest coverage
-3.1
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$1.09M
Latest balance sheet
Cash & equivalents
$1.09M
Total assets
$5.06M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$369,000
Capital expenditures (TTM)
$36,000
R&D (TTM)
$646,000
SG&A (TTM)
—
Stock compensation (TTM)
$250,000
R&D / revenue
6.8%
Stock compensation / revenue
2.6%

Ownership (13F)

9 metrics
13F filers
—
13F filer change QoQ
—
Institutional ownership
—
Conviction holders (share of 13F filers)
—
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
—
Holder tenure
—
Price vs estimated holder cost
—

Ownership (registered funds)

1 metrics
Index-fund ownership
0.0%

Short interest

3 metrics
Short interest
0.0%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
26 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$10,497
Insider-sentiment score
40 / 100

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1355790 CUSIP 460378201 Visit website Investor relations